Verrica Pharmaceuticals Inc (VRCA)

NASDAQ
Currency in USD
0.81
-0.07(-8.02%)
Closed·
After Hours
0.79-0.02(-2.47%)
·
VRCA Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
VRCA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.770.90
52 wk Range
0.388.98
Key Statistics
Edit
Prev. Close
0.87
Open
0.85
Day's Range
0.77-0.9
52 wk Range
0.38-8.98
Volume
445.76K
Average Volume (3m)
424.87K
1-Year Change
-90.45%
Book Value / Share
-0.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VRCA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.00
Upside
+393.83%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Employees
71

Verrica Pharmaceuticals Inc SWOT Analysis


YCANTH's Rocky Road
Explore Verrica's struggles with YCANTH's launch, facing negative revenues and market penetration challenges despite strategic efforts to improve distribution
Leadership Shake-Up
Delve into Verrica's management overhaul and strategic review, aimed at salvaging YCANTH's position and restoring financial stability amid operational hurdles
VP-315: A New Hope
Learn about Verrica's promising VP-315 for basal cell carcinoma, showing a 51% clearance rate in phase II trials, potentially diversifying the company's portfolio
Financial Crossroads
Analysts set price targets ranging from $2 to $14, reflecting uncertainty in Verrica's turnaround efforts and the critical nature of YCANTH's performance
Read full SWOT analysis

Verrica Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue reached $3.4M, driven by WICANT's 16.7% sequential growth in dispensed units, exceeding 10,000 quarterly for the first time
  • GAAP net loss of $9.7M ($0.10/share); Non-GAAP net loss of $7.8M ($0.08/share); Cash and equivalents at $29.6M as of March 31, 2025
  • Stock rose 8.63% in regular trading but fell 7.09% after hours; currently trades at $0.51, down 95% over the past year
  • Company focuses on WICANT commercialization and expanding to independent pharmacies; advancing BP315 for basal cell carcinoma
  • Analysts project 107% revenue growth this fiscal year; price targets range $2-$5; average recommendation 2.33
Last Updated: 14-05-2025, 02:50 am
Read Full Transcript

Compare VRCA to Peers and Sector

Metrics to compare
VRCA
Peers
Sector
Relationship
P/E Ratio
−1.1x−3.7x−0.5x
PEG Ratio
−0.030.000.00
Price/Book
−4.0x1.0x2.6x
Price / LTM Sales
10.4x2.2x3.1x
Upside (Analyst Target)
393.8%93.2%46.1%
Fair Value Upside
Unlock12.3%6.9%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.00
(+393.83% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.08 / -0.11
Revenue / Forecast
3.44M / 2.48M
EPS Revisions
Last 90 days

VRCA Income Statement

FAQ

What Is the Verrica Pharmaceuticals (VRCA) Stock Price Today?

The Verrica Pharmaceuticals stock price today is 0.81.

What Stock Exchange Does Verrica Pharmaceuticals Trade On?

Verrica Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Verrica Pharmaceuticals?

The stock symbol for Verrica Pharmaceuticals is "VRCA."

What Is the Verrica Pharmaceuticals Market Cap?

As of today, Verrica Pharmaceuticals market cap is 74.60M.

What Is Verrica Pharmaceuticals's Earnings Per Share (TTM)?

The Verrica Pharmaceuticals EPS (TTM) is -1.03.

When Is the Next Verrica Pharmaceuticals Earnings Date?

Verrica Pharmaceuticals will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is VRCA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Verrica Pharmaceuticals Stock Split?

Verrica Pharmaceuticals has split 0 times.

How Many Employees Does Verrica Pharmaceuticals Have?

Verrica Pharmaceuticals has 71 employees.

What is the current trading status of Verrica Pharmaceuticals (VRCA)?

As of 12 Jul 2025, Verrica Pharmaceuticals (VRCA) is trading at a price of 0.81, with a previous close of 0.87. The stock has fluctuated within a day range of 0.77 to 0.90, while its 52-week range spans from 0.38 to 8.98.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.